Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the pharmacokinetics and safety of WAL2014 capsules administered orally as a single dose to healthy adult male volunteers in double blind manner.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Talsaclidine | Experimental | single rising doses |
|
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Talsaclidine | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum concentration of the analyte in plasma (Cmax) | up to 24 hours after drug administration | |
| Time to reach maximum plasma concentration (tmax) | up to 24 hours after drug administration | |
| Area under the plasma concentration-time curve (AUC) | up to 24 hours after drug administration | |
| Distribution volume | up to 24 hours after drug administration | |
| Total clearance | up to 24 hours after drug administration | |
| Mean residence time (MRT) | up to 24 hours after drug administration | |
| Urinary excretion rate | up to 24 hours after drug administration | |
| Number of subjects with adverse events | up to 8 days after administration |
Not provided
Not provided
Inclusion Criteria:
Subjects for the study are healthy male adult volunteers who meet all the inclusion criteria listed below and do not fall into the exclusion criteria.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C079885 | talsaclidine fumarate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|